{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:16:06Z","timestamp":1795004166753,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ajo.2026.10.009","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:12:14Z","timestamp":1792717934000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association Between Systemic TNF-\u03b1 Inhibitor Use and Risk of Primary Open-Angle Glaucoma"],"prefix":"10.1016","volume":"293","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-6391","authenticated-orcid":false,"given":"ALEXANDER T.","family":"HONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4448-678X","authenticated-orcid":false,"given":"FOREST","family":"LIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1573-988X","authenticated-orcid":false,"given":"BENJAMIN Y.","family":"XU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-3202","authenticated-orcid":false,"given":"ROBERT N.","family":"WEINREB","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2026.10.009_bib0001","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ajo.2026.10.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100916","article-title":"Inflammation in glaucoma: from the back to the front of the eye, and beyond","volume":"83","author":"Baudouin","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2026.10.009_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101303","article-title":"The relationship between intraocular pressure and glaucoma: an evolving concept","volume":"103","author":"Asrani","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2026.10.009_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1640110","article-title":"Glial-mediated immune modulation in glaucomatous neurodegeneration: mechanisms and therapeutic implications","volume":"16","author":"Zong","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ajo.2026.10.009_bib0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti\u2013tumor necrosis factor therapy and incidence of Parkinson Disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.ajo.2026.10.009_bib0006","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40263-016-0374-z","article-title":"Treatment for rheumatoid arthritis and risk of Alzheimer\u2019s disease: a nested case-control analysis","volume":"30","author":"Chou","year":"2016","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ajo.2026.10.009_bib0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3","article-title":"Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head","volume":"32","author":"Yuan","year":"2000","journal-title":"Glia"},{"issue":"49","key":"10.1016\/j.ajo.2026.10.009_bib0008","doi-asserted-by":"crossref","first-page":"12633","DOI":"10.1523\/JNEUROSCI.2801-06.2006","article-title":"Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma","volume":"26","author":"Nakazawa","year":"2006","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"7","key":"10.1016\/j.ajo.2026.10.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040065","article-title":"Etanercept, a widely used inhibitor of tumor necrosis factor-\u03b1 (TNF-\u03b1), prevents retinal ganglion cell loss in a rat model of glaucoma","volume":"7","author":"Roh","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ajo.2026.10.009_bib0010","first-page":"526","article-title":"Roles of tumor necrosis factor alpha gene polymorphisms, tumor necrosis factor alpha level in aqueous humor, and the risks of open angle glaucoma: a meta-analysis","volume":"19","author":"Xin","year":"2013","journal-title":"Mol Vis"},{"issue":"2","key":"10.1016\/j.ajo.2026.10.009_bib0011","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1167\/iovs.09-4247","article-title":"Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma","volume":"51","author":"Sawada","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.10.009_bib0012","article-title":"Tumor necrosis factor inhibitors","author":"Gerriets","year":"2025","journal-title":"StatPearls"},{"issue":"9","key":"10.1016\/j.ajo.2026.10.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70198","article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US Census","volume":"34","author":"Stein","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7624","key":"10.1016\/j.ajo.2026.10.009_bib0014","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.ajo.2026.10.009_bib0015","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajo.2026.10.009_bib0016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.ajo.2026.10.009_bib0017","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ajo.2026.10.009_bib0018","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0079-6123(08)01128-X","article-title":"TNF-\u03b1 signaling in glaucomatous neurodegeneration","volume":"173","year":"2008","journal-title":"Prog Brain Res"},{"issue":"7","key":"10.1016\/j.ajo.2026.10.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040065","article-title":"Etanercept, a widely used inhibitor of tumor necrosis factor-\u03b1 (TNF- \u03b1), prevents retinal ganglion cell loss in a rat model of glaucoma","volume":"7","author":"Roh","year":"2012","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.ajo.2026.10.009_bib0020","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1111\/aos.15786","article-title":"The prophylactic value of TNF-\u03b1 inhibitors against retinal cell apoptosis and optic nerve axon loss after corneal surgery or trauma","volume":"102","author":"Paschalis","year":"2024","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"12","key":"10.1016\/j.ajo.2026.10.009_bib0021","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/ICO.0000000000002106","article-title":"Glaucoma after corneal trauma or surgery-A rapid, inflammatory, IOP-independent pathway","volume":"38","author":"Dohlman","year":"2019","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.ajo.2026.10.009_bib0022","first-page":"1787","article-title":"TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes","volume":"42","author":"Tezel","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2026.10.009_bib0023","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1167\/iovs.09-4247","article-title":"Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma","volume":"51","author":"Sawada","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.10.009_bib0024","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/OPTH.S19453","article-title":"Tumor necrosis factor-alpha (TNF-\u03b1) levels in aqueous humor of primary open angle glaucoma","volume":"5","author":"Balaiya","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"17","key":"10.1016\/j.ajo.2026.10.009_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11175232","article-title":"Factors associated with elevated tumor necrosis factor-\u03b1 in aqueous humor of patients with open-angle glaucoma","volume":"11","author":"Jung","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.ajo.2026.10.009_bib0026","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/MIB.0b013e31828132cb","article-title":"Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review","volume":"19","author":"Lopez","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.ajo.2026.10.009_bib0027","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T11:19:16Z","timestamp":1795000756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426005659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":27,"alternative-id":["S0002939426005659"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.10.009","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Systemic TNF-\u03b1 Inhibitor Use and Risk of Primary Open-Angle Glaucoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}